Valuation: Alumis Inc.

Market Cap 867M 772M 716M 648M 1.22B 82.19B 1.24B 8.57B 3.37B 43B 3.25B 3.19B 137B P/E 2026 *
-2.05x
P/E 2027 * -2.38x
Enterprise Value 151M 135M 125M 113M 213M 14.33B 216M 1.49B 587M 7.5B 567M 555M 23.93B EV / Sales 2026 *
24.2x
EV / Sales 2027 * 14.5x
Free-Float
96.45%
Yield 2026 *
-
Yield 2027 * -
1 day+5.68%
1 week-5.10%
Current month-9.34%
1 month-13.77%
3 months-76.62%
6 months-73.19%
Current year-31.35%
1 week 6.01
Extreme 6.01
6.72
1 month 6.01
Extreme 6.01
8.14
Current year 6.01
Extreme 6.01
31.35
1 year 4.37
Extreme 4.37
31.35
3 years 2.76
Extreme 2.7601
31.35
5 years 2.76
Extreme 2.7601
31.35
10 years 2.76
Extreme 2.7601
31.35
Manager TitleAgeSince
Chief Executive Officer 61 2021-09-22
Director of Finance/CFO 60 2022-04-30
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 60 2021-05-31
Chairman 61 2021-09-22
Director/Board Member 55 2022-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/26
Samsara BioCapital LLC
SellCompany -642,712 0.5207%
9/4/26 Other

Director

0 0%
8/3/26 Sell

Chief Technology Officer

-2,447 0.0020%
Change 5-day change 1-year change 3-year change Capi.($)
+5.68%-5.10%+49.22% - 821M
+0.79%-6.46%+52.86%+71.34% 65.83B
+1.92%+8.89%+12.90%+82.75% 51.87B
+6.91%+6.41%+9.61%+73.07% 51.2B
+0.74%+2.15%+30.95%+43.43% 43.76B
+3.87%+9.73%+21.52%+142.33% 42.09B
+7.91%+1.34%+263.31%+577.76% 39.04B
-0.40%+9.42%+18.44%+59.06% 34B
+3.84%-4.94%+42.35%+8.92% 25.2B
+2.36%+4.62%+24.20%+31.02% 22.8B
Average +3.36%-0.56%+52.53%+121.07% 37.66B
Weighted average by Cap. +3.06%+0.59%+51.69%+122.72%

Financials

2026 *2027 *
Net sales 6.26M 5.58M 5.17M 4.68M 8.81M 593M 8.93M 61.86M 24.31M 310M 23.48M 23M 991M 24.33M 21.67M 20.09M 18.2M 34.22M 2.31B 34.71M 240M 94.49M 1.21B 91.28M 89.38M 3.85B
Net income -427M -381M -353M -320M -601M -40.5B -610M -4.22B -1.66B -21.19B -1.6B -1.57B -67.63B -409M -364M -337M -306M -575M -38.73B -583M -4.04B -1.59B -20.26B -1.53B -1.5B -64.68B
Net Debt -716M -638M -591M -535M -1.01B -67.86B -1.02B -7.07B -2.78B -35.51B -2.69B -2.63B -113B -514M -458M -424M -384M -723M -48.7B -733M -5.08B -2B -25.48B -1.93B -1.89B -81.33B
Projected Income Statement - Annual - Alumis Inc.
Logo Alumis Inc.
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Employees
238
Date Price Change Volume
26-10-20 US$6.700 +5.68% 1,534,284
26-10-19 US$6.340 +3.59% 1,483,718
26-10-16 US$6.120 -3.01% 2,496,575
26-10-15 US$6.310 +4.13% 2,786,515
26-10-14 US$6.060 -7.62% 2,298,082
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Alumis Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
6.340USD
Average target price
31.12USD
Spread / Average Target
+390.93%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alumis Inc.
  1. Stock Market
  2. Stocks
  3. ALMS Stock